Magnus Persson proposed new Board member of Immunicum

Gothenburg, Sweden, 2015-08-13 15:15 CEST (GLOBE NEWSWIRE) — The Nomination Committee of Immunicum AB (publ) proposes that Magnus Persson be elected as a new member of the Board at the Annual General Meeting (December 3, 2015).

Dr. Magnus Persson has fifteen years of experience in venture capital at partner level in life science. He has founded and worked as Chairman and board member in numerous private and public biotech and medtech companies in Scandinavia, Europe and the United States.

Ongoing assignments as Chairman of Swedish companies include Karolinska Institute Innovations AB, Galecto Biotech and SLS Invest AB. He is also a member of the Board of Gyros AB. Ongoing international assignments include Cerecor Inc. and Medical Prognosis Institute ApS.

Magnus Persson received his medical training at the Karolinska Institute and Harvard Medical School, Boston, USA. He is Associate Professor of Physiology at the Karolinska Institute.

“Magnus has with his experience as a partner at HealthCap and The Column Group, based in California, amassed an extensive and successful experience of board work in companies that are in a similar stage of development as Immunicum,” said Nominating Committee Chairman, Evert Carlsson.


For further information, please contact:

Agneta Edberg, Chairman of the Board, Immunicum

Tel: 0709-104222,

Evert Carlsson, Nominating Committee Chairman, Immunicum

Tel: 0705-908224


The Company’s Certified Adviser is Redeye AB

Phone: +46 (0) 8 545 013 31.


About Immunicum AB (publ)

Immunicum AB (publ) develops vaccines for the treatment of tumor diseases. A phase II study of the Company’s most advanced project – INTUVAX® against renal cancer – has been initiated. The project portfolio contains an additional clinical phase I/II project in liver cancer.

Keep reading

Immunicum strengthens the clinical organization